Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials

Fig. 2

Hazard ratios (combination versus monotherapy) for progression-free and overall survival in different age cohorts. (Adjusted for gender, Eastern Co-operative Oncology Group performance status, disease stage, haemoglobin, white blood cell count, neutrophil count, and bilirubin). CI: confidence interval, PFS: progression-free survival, OS: overall survival

Back to article page